INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 177 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2020. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,315,520 | -17.7% | 140,440 | 0.0% | 0.01% | -25.0% |
| Q2 2023 | $8,892,661 | +7.1% | 140,440 | -8.4% | 0.01% | +14.3% |
| Q1 2023 | $8,306,339 | -13.1% | 153,395 | -15.1% | 0.01% | -12.5% |
| Q4 2022 | $9,560,421 | +0.6% | 180,658 | -11.5% | 0.01% | -11.1% |
| Q3 2022 | $9,502,000 | +77.2% | 204,223 | +117.4% | 0.01% | +80.0% |
| Q2 2022 | $5,361,000 | +47.2% | 93,919 | +57.8% | 0.01% | +66.7% |
| Q1 2022 | $3,641,000 | -14.1% | 59,506 | -52.3% | 0.00% | 0.0% |
| Q1 2021 | $4,237,000 | -9.5% | 124,863 | -15.2% | 0.00% | -25.0% |
| Q4 2020 | $4,683,000 | +42.6% | 147,265 | +15.1% | 0.00% | +33.3% |
| Q3 2020 | $3,283,000 | +5.1% | 127,930 | +5.1% | 0.00% | 0.0% |
| Q2 2020 | $3,124,000 | +100.5% | 121,680 | +20.1% | 0.00% | +50.0% |
| Q1 2020 | $1,558,000 | -48.6% | 101,348 | +14.6% | 0.00% | -33.3% |
| Q4 2019 | $3,033,000 | +478.8% | 88,400 | +26.1% | 0.00% | +200.0% |
| Q3 2019 | $524,000 | -31.7% | 70,100 | +18.6% | 0.00% | 0.0% |
| Q2 2019 | $767,000 | -43.3% | 59,100 | -46.8% | 0.00% | -50.0% |
| Q1 2019 | $1,353,000 | +111.4% | 111,100 | +97.7% | 0.00% | +100.0% |
| Q4 2018 | $640,000 | -46.8% | 56,200 | +1.3% | 0.00% | -50.0% |
| Q3 2018 | $1,204,000 | +15.3% | 55,505 | -6.1% | 0.00% | +100.0% |
| Q2 2018 | $1,044,000 | -3.5% | 59,105 | +15.0% | 0.00% | -50.0% |
| Q1 2018 | $1,082,000 | +45.4% | 51,400 | 0.0% | 0.00% | +100.0% |
| Q4 2017 | $744,000 | -8.3% | 51,400 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $811,000 | +27.1% | 51,400 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $638,000 | -23.6% | 51,400 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $835,000 | +3.1% | 51,400 | -4.3% | 0.00% | 0.0% |
| Q4 2016 | $810,000 | -1.0% | 53,700 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $818,000 | -63.4% | 53,700 | -6.6% | 0.00% | -75.0% |
| Q2 2016 | $2,232,000 | +35.4% | 57,500 | -3.0% | 0.00% | +33.3% |
| Q1 2016 | $1,649,000 | -61.0% | 59,300 | -24.7% | 0.00% | -57.1% |
| Q4 2015 | $4,233,000 | +712.5% | 78,700 | +505.4% | 0.01% | +600.0% |
| Q3 2015 | $521,000 | – | 13,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |